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ABSTRACT Psoriasis is a chronic inflammatory dermatosis that has a substantial im-
pact on the quality of life. Goeckerman’s technique (GT) has been implemented for 
the treatment of psoriasis with high clearance rates and long periods of remission. The 
objective of this article was to evaluate the efficacy and safety of modified GT (crude 
coal tar 2.5% plus UVA) as an alternative therapeutic modality for psoriatic patients 
with skin types III-V. Twenty two patients with moderate, severe, and erythrodermic 
psoriasis were included in this study. All patients received modified GT (crude coal tar 
2.5% plus UVA) six days per week for a period of 3 months. Assessment of the rate of 
reduction of psoriasis area severity index (PASI) was performed, as well as photograph-
ic documentation of each patient at baseline and after completion of therapy. There 
was a significant reduction in PASI scores after therapy in all patients (P=0.001). The 
rate of PASI reduction after therapy was >50% in 63.6% of patients; 27.3% of patients 
achieved >75% reduction and 9.1% of patients achieved 26-50% reduction. No serious 
side effects were reported in any of the patients. Modified GT is a safe and effective 
therapeutic option for patients with moderate and severe psoriasis. 
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INTRODUCTION
Psoriasis is a chronic inflammatory dermatosis that 
affects about 0.6-4.8% of the general population (1). 
It has a substantial impact on the quality of life which 
is comparable to that of major medical illnesses such 
as cancer, diabetes, and heart disease (2).
Currently, there is no treatment available for pso-
riasis. The current therapeutic approaches are fo-
cused only on alleviation of inflammation (3). In 1925, 
Goeckerman first described the clinical efficacy of 
UVB radiation combined with coal tar for the treat-
ment of psoriasis, resulting in high clearance rates 
and long periods of remission (4). Although the use 
of coal tar has waned in western countries, it is still 
considered the first-line treatment in many parts of 
the world (5,6). Coal tar is a proven remedy as evi-
denced by clinical experience and trials conducted 
on patients with various skin disorders (7). Currently, 
it is used mainly for chronic stable plaque psoriasis, 
scalp psoriasis, seborrheic dermatitis, and atopic der-
matitis (8).
The original Goeckerman’s technique (GT) for 
treatment of psoriasis was based on daily application 
of pharmacy grade coal tar (pix lithanthracis) to the 
affected skin with subsequent exposure of the body 
surface to UVB radiation (9).
The mechanism of action of topical coal tar and 
UVB has not been clearly elucidated. However, there 
are several possible effects that have been suggested, 
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including suppression of DNA synthesis, reduction of 
epidermal hyperproliferation, modulation of pro-in-
flammatory cytokines, depletion of T-lymphocytes, 
and inhibition of angiogenesis (10-12). 
Coal tar has a photosensitizing effect within the 
range of 330 to 550 nm in the UVA and visible light 
spectrum (8). The current application of GT uses UVB 
(290-311 nm). The use of UVB is justified, despite be-
ing outside the spectrum of coal tar photosensitiza-
tion, to avoid the possible phototoxic effects of UVA 
especially in skin types I-II (10).  
Several modifications of the use of coal tar fol-
lowed by UVB radiation have been tried in the treat-
ment of psoriasis with variable degrees of success, 
before the implementation of narrow-band (NB) UVB 
which has a wavelength close to the photosensitizing 
spectrum of crude coal tar (8,25,26,30). 
The combination of coal tar and UVA radiation is 
known for its suppressive effect on DNA synthesis in 
normal-appearing and proliferating skin in mouse 
models, that was more extensive compared to the 
use of coal tar alone (13). This suppression of DNA 
synthesis has not been observed with either UVB or 
UVC (14). Although UVA radiation is on that part of 
the spectrum that activates coal tar, it has not been 
used because of its potential phototoxic reactions es-
pecially in patients with white skin (15).
Accordingly, the current study was conducted to 
evaluate the efficacy and safety of modified GT (crude 
coal tar 2.5% plus UVA instead of UVB which was used 
in the original GT) as an alternative therapeutic mo-
dality for psoriatic patients with skin types III-V.
PATIENTS AND METHODS
Patients
This prospective clinical study included 22 pa-
tients with moderate, severe, and erythrodermic 
psoriasis (12 women and 10 men). The study was 
approved by the Dermatology Research Ethics Com-
mittee (REC). Written informed consent was obtained 
from all patients before conducting the study. 
Any previous systemic medication for psoriasis 
was discontinued for three months before conduct-
ing the study, and only topical emollients were al-
lowed.
Patients aged <13 years and >60 years as well as 
pregnant and lactating women were excluded. All 
patients were skin types III-V according to Fitzpatrick 
skin type criteria.
Each patient was subjected to the following: Full 
history taking (age, sex, medical condition, previous 
anti-psoriasis therapy) and thorough clinical exami-
nation, and psoriasis area severity index (PASI) score 
evaluation  was performed for each patient before 
and after completion of therapy. Routine investiga-
tions (complete blood picture, liver function tests, 
kidney function tests, blood sugar, and ophthalmo-
logic consultation) were done for each patient. 
Methods
Modified Goeckerman technique
All patients recruited in this study were instructed 
to do the following steps: Take a shower and then ap-
ply crude coal tar 2.5% in petrolatum to the whole 
body except face and genitals for at least 6 hours. Af-
terwards, the tar was removed using cotton soaked 
with vegetable oil. Patients were instructed not to 
remove the whole application and leave traces of tar 
over their body. This procedure was carefully moni-
tored by a fixed investigator for all patients. After at 
least 8 hours, each patient was exposed to UVA radia-
tion. These steps were repeated 6 days per week for a 
period of 3 months. This technique added two modi-
fications to the original GT which are: The application 
of coal tar for 6 hours only instead of overnight and 
the usage of UVA radiation instead of UVB.
•  UVA irradiation (broad-band UVA: 320-400 nm); Ra-
diation source UVA 1000; Waldman lighting cabin 
(Germany) equipped with 26 UVA lamps, having 
a radiation spectrum of 315 nm to 400 nm with a 
peak at 365 nm; Patients started at a dose of 0.5 
J/cm2; Doses were increased by increments of 20% 
according to patient response and tolerance.
Patient Assessment
The following grading system was utilized to as-
sess the efficacy of modified GT through the mea-
surement of the PASI reduction rate after completion 
of therapy: Grade 1: 0-25% reduction (poor); Grade 2: 
26-50% reduction (fair); Grade 3: 51-75% reduction 
(good); Grade 4: >75% reduction (excellent). Photo-
graphic documentation was kept for each patient at 
baseline and at the end of the study.
Side effects
Adverse effects from tar application and/or UVA 
radiation were recorded during the study period, 
such as phototoxic reactions (itching, burning, ery-
thema) and side effects of coal tar (local irritation, tar 
folliculitis, acneiform eruption, phototoxic reaction, 
and contact allergy).
Follow-up period
All recruited patients were followed up for a peri-
od of one year after cessation of therapy to determine 
the duration of remission and the rate of relapse.
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Statistical analysis
Data were statistically described in terms of 
range, mean ± standard deviation (±SD). Comparison 
of PASI pre and post treatment was done using Wil-
coxon signed-rank test for paired (matched) samples. 
P values less than 0.05 were considered statistically 
significant. All statistical calculations were done using 
computer programs Microsoft Excel 2007 (Microsoft 
Corporation, NY, USA) and SPSS (Statistical Package 
for the Social Science; SPSS Inc., Chicago, IL, USA) ver-
sion 15 for Microsoft Windows.
RESULTS
Twenty two patients (12 women (54.5%) and 10 
men (45.5%)) were included in this study. Their ages 
ranged between 13-60 years (36.6±14.5). Thirteen pa-
tients (59.1%) had erythrodermic psoriasis, 6 (27.3%) 
had severe psoriasis, and 3 (13.6%) suffered from 
moderate psoriasis according to the PASI score. 
When comparing PASI scores before and after 3 
months of modified GT, a significant statistical dif-
ference was found in all patients (n=22), where the 
mean PASI score before treatment was 39.631±19.475 
and 14.143±9.673 after treatment  (P=0.001) (Figure 
1). The rate of PASI reduction after therapy was >50% 
(good response) (Grade 3) in 63.6% (n=14) of the pa-
tients, while 27.3% (n=6) of the patients had an ex-
cellent response (Grade 4) (>75% reduction) and two 
patients (9.1%) had fair response (Grade 2) (26-50% 
reduction) (Figures 1, 2, 3).
The mean value of the cumulative UVA dose re-
ceived by each patient was 184.71±SD 2.72, through-
out the duration of the study.
There were no serious side effects reported in any 
of the patients, apart from mild irritant dermatitis in 
two patients and mild folliculitis in another due to tar 
application.
Follow-up period
Thirteen patients stayed in remission for a period 
of 8 months and 5 patients stayed in remission for 6 
months after cessation of therapy. These patients ap-
plied only topical emollients during the remission pe-
riod. Four patients had a relapse of psoriasis (return of 
psoriatic lesions to PASI score prior to therapy) within 
one month of cessation of GT; three of them agreed 
to repeat GT, while the fourth patient was shifted to 
another modality.
DISCUSSION
All patients enrolled in this study achieved a sta-
tistically significant reduction in PASI score after re-
ceiving treatment with a modified Goeckerman tech-
nique (UVA instead of BB-UVB combined with topical 
coal tar 2.5%), and most of our patients had a long 
remission period ranging from six to eight months.
During the past century, many modifications have 
been made to the original Goeckerman regimen to 
make it more practical as outpatient treatment. Data 
have accumulated both supporting and questioning 
the efficacy of this approach (16-20). The crude coal 
tar preparations available today range from 1%-5% in 
petrolatum, starch, and zinc oxide (21).
In this study, we adopted another modification 
to the classic GT by using UVA instead of broad band 
UVB. To our knowledge, this modification has not 
been reported in the literature. The use of coal tar 
with near UVA light leads to the suppression of DNA 
synthesis in normal-appearing and proliferating skin 
in mouse models, greater than when coal tar is used 
alone (13). This suppression of DNA synthesis has not 
been noted with either UVB or UVC treatment (14). Al-
though UVA light contains that part of the spectrum 
Figure 1. A: Rate of reduction of psoriasis area se-
verity index (PASI) after modified Goeckerman’s 
technique (GT), where 9.1% of patients showed fair 
response, 63.6% showed good response, and 27.3% 
showed excellent response. B: Psoriasis area sever-
ity index (PASI) score at baseline and 3 months after 
modified GT, showing significant reduction in all pa-
tients (n=22).
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that activates coal tar, it has not been used because of 
its known phototoxic reactions, especially in patients 
with white skin (15).
The mechanism of action of topical coal tar is not 
well understood. However, there are several possible 
effects including suppression of DNA synthesis lead-
ing to a reduction of epidermal hyperproliferation 
in psoriatic skin (10-12). Conversely, it increases the 
mitotic rate labeling index and initially thickens the 
epidermis in healthy skin (21). This variance in activity 
may be because coal tar is correcting a defect in dif-
ferentiation in psoriatic skin. In addition, antibacterial, 
antifungal, and anti-parasitic effects have been de-
scribed, as well as anti-pruritic and anti-inflammatory 
effects (8,22). Recently, it has been shown that the 
number of immunoregulatory T cells (Tregs) increased 
in psoriatic patients after GT, which is likely associated 
with amelioration of inflammation by GT (23).
The results of the current study show that at the 
end of 12 weeks, 27.3% of patients achieved PASI 75 
(>75% reduction) and 63.6% achieved >50% reduc-
tion in their PASI scores after modified GT, which is es-
pecially significant considering most of the patients 
enrolled in this study suffered from severe and eryth-
rodermic psoriasis. 
Leon et al. reviewed the efficacy and safety of the 
most scientifically acceptable clinical trials published 
for psoriasis therapy from 1986 to 2006. The percent-
age of PASI 75 reduction at week 12 obtained by 
Goeckerman (classic technique with BB-UVB) therapy 
and retinoid plus psoralen plus UVA (Re-PUVA) was 
100%, compared with 49% and 34% for etanercept 
50 mg twice weekly and 25 mg twice weekly respec-
tively, 31.4% for efalizumab, and 21% for alefacept. 
The authors concluded that the risk-benefit was more 
favorable for Goeckerman therapy and Re-PUVA. It is 
noteworthy to mention that GT does not include the 
use of systemic retinoids used in the Re-PUVA regi-
men, thus avoiding the possible side effects occur-
ring with systemic retinoid therapy (24).
Figure 2. A female patient aged 25 years with eryth-
rodermic psoriasis. A: The face of the patient at base-
line with scaly erythematous lesions. B: The face 3 
months after modified Goeckerman’s technique (GT). 
C: The anterior view of both lower limbs at baseline. 
D: The anterior view of both lower limbs 3 months af-
ter modified GT. E: The posterior view of both lower 
limbs at baseline. F: The posterior view of both lower 
limbs 3 months after modified GT. Photos B, D, and F 
show an excellent response (Grade 4).
Figure 3. A female patient aged 20 years with eryth-
rodermic psoriasis. A: The anterior view of the trunk 
at baseline with diffuse erythema and scaling. B: The 
anterior view of the trunk 3 months after modified 
Goeckerman’s technique (GT). C: The posterior view 
of the trunk at baseline with diffuse erythema and 
scaling. D: The posterior view of the trunk 3 months 
after modified GT. Photos B and D show an excellent 
response (Grade 4).
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In addition, Chern et al., using modified Goeck-
erman therapy (narrow-band UVB), demonstrated 
that 56.2% of their patients achieved PASI 75 (>75% 
reduction) (25). Lee and Koo also used the modified 
“ultra” Goeckerman therapy with narrow-band UVB, 
showing that this treatment was effective for pso-
riasis resistant to both prebiologic therapies, such as 
cyclosporin, methotrexate, or phototherapy, and bio-
logic treatments. They reported that all their patients 
(n=25) achieved PASI 75 by week 12 (26).
Two recent clinical trials have demonstrated the 
efficacy and safety of GT for the treatment of severe 
generalized psoriasis as well as psoriasis refractory to 
biologic therapy (27,28). 
Remission rates for Goeckerman treatment have 
been reported to be 1.7-1.8 years (29). One study 
showed average remission rates of up to 1 year (1). 
Other studies in the literature reported that Goeck-
erman therapy induces remission for a minimum of 
6-8 months (30,31). This duration is similar to the one 
achieved in our study (13 patients stayed in remission 
for 8 months and 5 patients had a remission period 
of 6 months).  
In our study, most of the patients reported resis-
tance to conventional therapeutic modalities (meth-
otrexate, retinoids, and phototherapy) but showed a 
dramatic response to modified GT (63.6% of the pa-
tients achieved >50% reduction of PASI after thera-
py). 
Possible side effects of coal tar include local irri-
tation, tar folliculitis, acneiform eruption, phototoxic 
reaction, and contact allergy.
In this study, 3 out of 22 patients (13.6%) expe-
rienced side effects from tar application in the form 
of folliculitis and irritant contact dermatitis. Further-
more, none of the patients suffered from phototoxic-
ity from UVA exposure. These results are in contrast to 
what has been reported in literature about the high 
risk of phototoxic reactions that occur with UVA expo-
sure (30). The fact that patients who were recruited in 
this study did not suffer from phototoxic reactions af-
ter UVA exposure is probably due to their pigmented 
skin (skin types III-V). This observation is supported 
by Hinds and Heald who reported that patients with 
pigmented skin may achieve maximal levels of light 
exposure (20-30 minutes of UVA light) and not show 
phototoxicity (32).
Regarding the cost of different therapeutic mo-
dalities for psoriasis, GT is becoming an attractive 
modality for many patients with moderate to severe 
psoriasis, being a relatively cost-effective treatment 
option. In contrast, other options including biologics 
are quite expensive, lack long-term remission effects, 
and carry a high risk of serious side effects as a result 
of immunosuppression (1). These findings are sup-
ported by the consensus of the Canadian Psoriasis 
Expert Panel (33) and the Czech Republic (34) which 
consider Goeckerman treatment as a first-line thera-
py for psoriasis because of its low cost and long-term 
efficacy.
CONCLUSION
Goeckerman therapy is reemerging as a standard 
therapeutic option for patients with moderate and 
severe psoriasis. It stands out as a low-cost, safe, and 
effective modality for a chronic and potentially in-
capacitating disease. Furthermore, our modification 
(UVA phototherapy) could offer another safe and ef-
fective way of implementing this old technique for 
treating psoriatic patients with skin types III-V.
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